1. Home
  2. AMAL vs IVA Comparison

AMAL vs IVA Comparison

Compare AMAL & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amalgamated Financial Corp. (DE)

AMAL

Amalgamated Financial Corp. (DE)

HOLD

Current Price

$41.89

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Logo Inventiva S.A. American Depository Shares

IVA

Inventiva S.A. American Depository Shares

HOLD

Current Price

$5.53

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMAL
IVA
Founded
1923
2011
Country
United States
France
Employees
N/A
77
Industry
Commercial Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.1B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
AMAL
IVA
Price
$41.89
$5.53
Analyst Decision
Hold
Strong Buy
Analyst Count
3
10
Target Price
$36.00
$16.20
AVG Volume (30 Days)
112.8K
345.9K
Earning Date
04-23-2026
03-30-2026
Dividend Yield
1.63%
N/A
EPS Growth
N/A
N/A
EPS
3.41
N/A
Revenue
N/A
N/A
Revenue This Year
$21.18
N/A
Revenue Next Year
$6.55
$1,062.21
P/E Ratio
$12.21
N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.13
$2.94
52 Week High
$42.66
$7.98

Technical Indicators

Market Signals
Indicator
AMAL
IVA
Relative Strength Index (RSI) 69.34 47.49
Support Level $36.56 $3.86
Resistance Level $42.66 $6.50
Average True Range (ATR) 0.84 0.40
MACD 0.37 -0.02
Stochastic Oscillator 90.86 49.81

Price Performance

Historical Comparison
AMAL
IVA

About AMAL Amalgamated Financial Corp. (DE)

Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management and trust and custody services.

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

Share on Social Networks: